Moreover, IGF1R, TNPO1 and FASN are experimentally validated targets for TFAP2A, as annotated by RegNetwork software, and are involved in multiple cancer stemness and drug resistance processes30,33–35. The gene discussed is IGF1R; the disease is cancer.